Omega-3 fatty acids, inflammation and angiogenesis: Nutrigenomic effects as an explanation for anti-atherogenic and anti-inflammatory effects of fish and fish oils

Journal of Nutrigenetics and Nutrigenomics

Volumn 1, Issue 1-2, 2008, Pages 4-23

  Massaro, Marika ^a,b   Scoditti, Egeria ^a,b   Carluccio, Maria Annunziata ^a,b   Montinari, Maria Rosa ^b   De Caterina, Raffaele ^a,c  

^a CNR   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Adhesion molecules; Atherosclerosis; Cyclooxygenase 2; Endothelial activation; Endothelium; n 3 fatty acids; Omega 3 fatty acids; Plaque angiogenesis; Plaque rupture

Indexed keywords

ANGIOSTATIN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; FUMAGILLOL CHLOROACETYLCARBAMATE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LINOLEIC ACID; LYSOPHOSPHATIDYLCHOLINE; MEMBRANE PHOSPHOLIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OMEGA 9 FATTY ACID; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CELL INTERACTION; CELL MEMBRANE; ENDOTHELIUM CELL; FISH; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; NUTRIENT; NUTRIGENOMICS; PRIORITY JOURNAL; REVIEW;

EID: 35648984449     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000109871     Document Type: Review

References (146)

1. De Caterina R: Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 2000;3:453-467.
2. De Caterina R, Massaro M, Libby P: Endothelial functions and dysfunctions; in De Carerina R, Libby P (eds): Endothelial Dysfunction and Vascular Disease, Blackwall Publishing, 2007, pp 3-17.
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
4. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
5. De Caterina R, Gimbrone MA Jr: Leukocyte-endothelial interactions and the pathogenesis of atherosclerosis; in Kristensen SD, Schmidt EB, De Caterina R, Endres S (eds): n-3 Fatty Acids - Prevention and Treatment in Vascular Disease. Berlin, Springer, 1995, pp 9-24.
6. De Caterina R, Cybulsky MA, Clinton SK, Gimbrone MA Jr, Libby P: Omega-3 fatty acids and endothelial leukocyte adhesion molecules. Prostagl Leukotr Ess Fatty Acids 1995;52:191-195.
7. Cybulsky MJ, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis VM, Gutierrez-Ramos J-C, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-1262.
8. Libby P: Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003;91(suppl):3A-6A.
9. Moulton KS: Plaque angiogenesis: its functions and regulation. Cold Spring Harbour Symp Quant Biol 2002;67:471-482.
10. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998;101:1551-1556.
11. Vancov V: Structural basis of the microcirculation in the wall of arterial vessels. Bibl Anat 1973;11:383-388.
12. Winternitz M, Thomas R, LeCompte P: The Biology of Atherosclerosis. Springfield, Thomas, 1938.
13. Geiringer E: Intimal vascularization and atherosclerosis. J Pathol Bacteriol 1951;63:201-211.
14. Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ: Hypothesis: Vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984;310:175-177.
15. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, Naylor AR, Brindle NP: Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999;30:261-268.
16. Mofidi R, Crotty TB, McCarthy P, Sheehan SJ, Mehigan D, Keaveny TV: Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001;88:945-950.
17. Kumamoto M, Nakashima Y, Sueishi K: Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995;26:450-456.
18. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J: Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-2061.
19. Bonn D: Blocking angiogenesis in diabetic retinopathy. Lancet 1996;348:604.
20. Rankin EB, Yu D, Jiang J, Shen H, Pearce EJ, Goldschmidt MH, Levy DE, Golovkina TV, Hunter CA, Thomas-Tikhonenko A: An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther 2003;2:687-693.
21. Chen C, Walterscheid JP: Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res 2006;99:787-789.
22. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, et al: Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993;92:945-951.
23. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE: Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996;93:672-682.
24. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J: Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732.
25. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD: Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001;37:2126-2130.
26. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429.
27. Gately S, Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31:2-11.
28. Leahy K, Koki A, Masferrer J: Role of cyclooxygenase in angiogenesis. Curr Med Chem 2000;7:1163-1170.
29. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-33160.
30. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF, Levine AC: Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002;277:50081-50086.
31. Hahn GL, Polgar PR: Prostaglandin production in phenotypically distinct cultured bovine pulmonary artery endothelium. Atherosclerosis 1984;51:143-150.
32. Kuwashima L, Graeber J, Glaser BM: Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest Ophthalmol Vis Sci 1988;29:1213-1220.
33. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99-107.
34. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
35. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002;277:27613-27621.
36. Dimmeler S, Zeiher AM: Akt takes center stage in angiogenesis signaling. Circ Res 2000;86:4-5.
37. Callejas N, Casado M, Diaz-Guerra M, Bosca L, Martin-Sanz P: Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001;33:860-867.
38. Choi YA, Lee DJ, Lim HK, Jeong JH, Sonn JK, Kang SS, Baek SH: Interleukin-1beta stimulates matrix metalloproteinase-2 expression via a prostaglandin E2-dependent mechanism in human chondrocytes. Exp Mol Med 2004;36:226-232.
39. Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, Breyer RM, Dannenberg AJ, Falcone DJ: Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 2006;281:3321-3328.
40. Dormond O, Bezzi M, Mariotti A, Ruegg C: Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002;277:45838- 45846.
41. Dormond O, Foletti A, Paroz C, Ruegg C: NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7:1041-1047.
42. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-293.
43. Schwacha MG, Chung CS, Ayala A, Bland KI, Chaudry IH: Cyclooxygenase 2-mediated suppression of macrophage interleukin-12 production after thermal injury. Am J Physiol 2002;282:C263-C270.
44. Schönbeck U, Sukkova G, Graber P, Coulter S, Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-1291.
45. Stemme V, Swedenborg J, Claesson H, Hansson GK: Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 2000;20:146-152.
46. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N: Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000;41:82-88.
47. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Erne P, Binder BR, Leitinger N: Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 2006;99:900-908.
48. Corcoran M, Stetler-Stevenson W, DeWitt D, Whal L: Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E 2 and matrix metalloproteinase production by human monocytes. Arch Biochem Biophys 1994;310:481-488.
49. 2-dependent plaque instability. Circulation 2001;104:921-927.
50. Dorn GW 2nd, Becker MW, Davis MG: Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 1992;267:24897-24905.
51. Okon EB, Szado T, Laher I, McManus B, van Breemen C: Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003;40:520-530.
52. Wohlfeil ER, Campbell WB: 25-Hydroxycholesterol increases eicosanoids and alters morphology in cultured pulmonary artery smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:2901-2908.
53. Wong ST, Baker LP, Trinh K, Hetman M, Suzuki LA, Storm DR, Bornfeldt KE: Adenylyl cyclase 3 mediates prostaglandin E(2)-induced growth inhibition in arterial smooth muscle cells. J Biol Chem. 2001;276:34206-34212.
54. Huttner JJ, Gwebu ET, Panganamala RV, Milo GE, Cornwell DC, Sharma HM, Geer JC: Fatty acids and their prostaglandin derivatives: Inhibitors of proliferation in aortic smooth muscle cells. Science 1977;197:289-291.
55. Cipollone F and Fazia ML: COX-2 and atherosclerosis. J Cardiovasc Pharmacol 2006;47(suppl 1):S26-S36.
56. Stacy ZA, Dobesh PP, Trujillo TC: Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 2006;26:919-938.
57. Bea F, Blessing E, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J, Rosenfeld ME: Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 2003;60:198-204.
58. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-1823.
59. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005;21:21.
60. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA: Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001;98:3358-3363.
61. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE: Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 2003;41:1812-1819.
62. Burr G, Burr M: A new deficiency disease produced by rigid exclusion of fat free diet. J Biol Chem 1929;82:345-367.
63. Burr G and Burr M: On the nature of fatty acids essential in nutrition. J Biol Chem 1930;86:345-367.
64. Department of Health: Nutritional Aspect of Cardiovascular Disease: Report of the Cardiovascular Review Group. London, HMSO, 1994.
65. Sprecher H: Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 2000;1486:219-231.
66. Yamazaki K, Fujikawa M, Hamazaki T, Yano S, Shono T: Comparison of the conversion rates of alpha-linolenic acid (18:3(n - 3)) and stearidonic acid (18:4(n - 3)) to longer polyunsaturated fatty acids in rats. Biochim Biophys Acta 1992;1123:18-26.
67. Burdge G: Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004;7:137-144.
68. Burdge GC, Jones AE, Wootton SA: Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr 2002;88:355-363.
69. Henderson R, Sargent J: Chain-length specificities of mitochondrial and peroxisomal beta-oxidation of fatty acids in livers of rainbow trout (Salmo gairdneri). Comp Biochem Physiol 1985;82B:79-85.
70. Linares F, Henderson R: Incorporation of 14C-labelled polyunsaturated fatty acids by juvenile turbot, Scophthalmus maximus (L.) in vivo. J Fish Biol 1991;38:335-347.
71. Tocher D, Sargent J: Effect of temperature on the incorporation into phospholipid classes and metabolism via desaturation and elongation of n-3 and n-6 polyunsaturated fatty acids in fish cells in culture. Lipids 1990;25:435-442.
72. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J: n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006;84:5-17.
73. Dyerberg J, Bang HO, Stofferson E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978;i:117-119.
74. Kromann N, Green A: Epidemiological studies in the Upernavik district, Greenland. Acta Med Scand 1980;208:401-406.
75. Newman WP, Middaugh JP, Propst MT, Rogers DR: Atherosclerosis in Alaska natives and non-natives. Lancet 1993;341:1056-1057.
76. Bang HO, Dyerberg J, Hjorne N: The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976;200:69-73.
77. Yano K, MacLean CJ, Reed DM, Shimizu Y, Sasaki H, Kodama K, Kato H, Kagan A: A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am J Epidemiol 1988;127:476-487.
78. Yuan JM, Ross RK, Gao YT, Yu MC: Fish and shellfish consumption in relation to death from myocardial infarction among men in Shanghai, China. Am J Epidemiol 2001;154:809-816.
79. Kromhout D, Bosschieter EB, De Lezenne Coulander C: The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-1209.
80. Norell SE, Ahlbom A, Feichting M, Pedersen NL: Fish consumption and mortality from heart disease. Br Med J 1986;283:426.
81. Nordoy A, Goodnight SH: Dietary lipids and thrombosis: relationships to atherosclerosis. Arteriosclerosis 1990;10:149-163.
82. Dolecek TA, Granditis G: Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 1991;66:205-216.
83. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-1118.
84. Hunter DJ, Kazda I, Chockalingam A, Fodor JG: Fish consumption and cardiovascular mortality in Canada: an inter-regional comparison. Am J Prev Med 1988;4:5-10.
85. Shimokawa H, Vanhoutte PM: Dietary omega-3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol 1989;256:H968-H973.
86. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC: Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977-982.
87. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH: Fish consumption and cardiovascular disease in the physicians' health study: A prospective study. Am J Epidemiol 1995;142:166-175.
88. De Caterina R, Madonna R, Hassan J, Procopio AD: Nutrients and gene expression. World Rev Nutr Diet 2001;89:23-52.
89. De Caterina R, Zampolli A, Del Turco S, Madonna R, Massaro M: Nutritional mechanisms that influence cardiovascular disease. Am J Clin Nutr 2005;in press.
90. Soei L, Lamers J, Sassen L, van Tol A, Scheek L, Dekkers D, van Meegen J, Verdouw P: Fish oil: A modulator of experimental atherosclerosis in animals; in Kristensen S, Endres S, De Caterina R, Schmidt E (eds): n-3 Fatty Acids: Prevention and Treatment in Vascular Disease. Berlin, Springer, 1995, pp 77-84.
91. Eritsland J, Arnesen H, Grønseth K, Field NB, Abdelnoor M: Effect of supplementation with n-3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from the SHOT study. Eur Heart J 1994;15:29.
92. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA, Libby P: The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb Vasc Biol 1994;14:1829-1836.
93. De Caterina R, Bernini W, Carluccio M, Liao J, Libby P: Structural requirements for inhibition of cytokine-induced endothelial activation by unsaturated fatty acids. J Lipid Res 1998;39:1062-1070.
94. Massaro M, Basta G, Lazzerini G, Carluccio M, Bosetti F, Solaini G, Visioli F, Paolicchi A, De Caterina R: Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb Haemost 2002;88:176-375.
95. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002;100:1340-1346.
96. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-1178.
97. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
98. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998;246:370-374.
99. Ziouzenkova O, Plutzky J: Lipolytic PPAR activation: New insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care 2004;7:369-375.
100. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 1995;2:261-266.
101. Desvregne B, Wahli W: Peroxisome proliferator-activated receptor: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
102. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPpar gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234.
103. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-366.
104. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-3131.
105. Mishra A, Chaudhary A, Sethi S: Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol 2004;24:1621-1627.
106. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-485.
107. Connolly JM, Gilhooly EM, Rose DP: Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice. Nutr Cancer 1999;35:44-49.
108. Rose DP, Connolly JM, Coleman M: Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin Cancer Res 1996;2:1751-1756.
109. Rose DP, Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol 1999;15:1011-1015.
110. Suzuki I, Iigo M, Ishikawa C, Kuhara T, Asamoto M, Kunimoto T, Moore MA, Yazawa K, Araki E, Tsuda H: Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int J Cancer 1997;73:607-612.
111. Harris MA, Hansen RA, Vidsudhiphan P, Koslo JL, Thomas JB, Watkins BA, Allen KG: Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukot Essent Fatty Acids 2001;65:23-29.
112. Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Palozza P: n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 2004;25:2303-2310.
113. Yang SP, Morita I, Murota SI: Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. J Cell Physiol 1998;176:342-349.
114. Kanayasu T, Morita I, Nakao-Hayashi J, Asuwa N, Fujisawa C, Ishii T, Ito H, Murota S: Eicosapentaenoic acid inhibits tube formation of vascular endothelial cells in vitro. Lipids 1991;26:271-276.
115. Tsuji M, Murota SI, Morita I: Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. Prostaglandins Leukot Essent Fatty Acids 2003;68:337-342.
116. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
117. Wang LH, Hajibeigi A, Xu XM, Loose-Mitchell D, Wu KK: Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun 1993;190:406-411.
118. Tanabe T, Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114.
119. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-7388.
120. Ramsay R, Ciznadija M, Vanevski M, Mantamadiotis T: Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 2003;16:59-67.
121. Pahl H, Baeuerle PA: Oxygen and the control of gene expression. Bioassays 1994;16:479-501.
122. Hayden MS, Ghosh S: Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
123. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR: Induction of cyclooxygenase-2 by the activated MEKK1 -> 1 SEK1/MKK4 -> 1 p38 mitogen-activated protein kinase pathway. J Biol Chem 1998;273:12901-12908.
124. Rikitake Y, Hirata K, Kawashima S, Takeuchi S, Shimokawa Y, Kojima Y, Inoue N, Yokoyama M: Signaling mechanism underlying COX-2 induction by lysophosphatidylcholine. Biochem Biophys Res Commun 2001;281:1291-1297.
125. Hirai K, Ezumi Y, Nishida E, Uchiyama T, Takayama H: Comparative study of vanadate-and phorbol ester-induced cyclo-oxygenase-2 expression in human endothelial cells. Thromb Haemost 1999;82:1545-1552.
126. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003;44:479-486.
127. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH: Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003;278:37041-37051.
128. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST: Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 2003;100:1751-1756.
129. Gilbert M, Dalloz S, Maclouf J, Lagarde M: Differential effects of long chain n-3 fatty acids on the expression of PGH synthase isoforms in bovine aortic endothelial cells. Prostaglandins Leukot Essent Fatty Acids 1999;60:363-365.
130. Ait-Said F, Elalamy I, Werts C, Gomard MT, Jacquemin C, Couetil JP, Hatmi M: Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta 2003;1631:77-84.
131. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB, De Caterina R: The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKCepsilon inhibition. Proc Natl Acad Sci USA 2006;103:15184-15189.
132. Cok SJ, Morrison AR: The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001;276:23179-23185.
133. Ma DW, Seo J, Switzer KC, Fan YY, McMurray DN, Lupton JR, Chapkin RS: n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 2004;15:700-706.
134. Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR: Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005;45:559-579.
135. 2-mediated activation of NFkappaB-inducing kinase. J Biol Chem 2006;281:1495-1505.
136. Ray R, Shah AM: NADPH oxidase and endothelial cell function. Clin Sci (Lond) 2005;109:217-226.
137. Rueckschloss U, Duerrschmidt N, Morawietz H: NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid Redox Signal 2003;5:171-180.
138. Chang MS, Chen BC, Yu MT, Sheu JR, Chen TF, Lin CH: Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK, pathways. Cell Signal 2005;17:299-310.
139. Li RC, Ping P, Zhang J, Wead WB, Cao X, Gao J, Zheng Y, Huang S, Han J, Bolli R: PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol 2000;279:H1679-H1689.
140. Jude S, Roger S, Martel E, Besson P, Richard S, Bougnoux P, Champeroux P, Le Guennec JY: Dietary long-chain omega-3 fatty acids of marine origin: A comparison of their protective effects on coronary heart disease and breast cancers. Prog Biophys Mol Biol 2006;90:299-325.
141. Li JM, Shah AM: Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002;277:19952-19960.
142. Touyz RM, Schiffrin EL: Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 2006;45:19-28.
143. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-4577.
144. Sakurai S, Alam S, Pagan-Mercado G, Hickman F, Tsai JY, Zelenka P, Sato S: Retinal capillary pericyte proliferation and c-Fos mRNA induction by prostaglandin D2 through the cAMP response element. Invest Ophthalmol Vis Sci 2002;43:2774-2781.
145. Ackman RG: Nutritional composition of fats in seafoods. Prog Food Nutr Sci 1989;13:161-289.
146. Racine RA, Deckelbaum RJ: Sources of the very-long-chain unsaturated omega-3 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Curr Opin Clin Nutr Metab Care 2007;10:123-128.